Schistosomiasis remains a public health problem in Egypt, despite the continuous control effort. Most of the anti-schistosomal drugs have deleterious side effects or low efficacy. This necessitates a search for new safe and effective drug. A field survey was done in Ezbet El-Bakly (Tamyia Center) El-Fayoum Governorate to determine the magnitude of schistosomiasis haematobium and mansoni and to evaluate the efficacy of Mirazid (the oleo-resin extract from Myrrh of Commiphora molmol tree, family: Burseraceae) in the treatment of both types of schistosomiasis. Among the 1019 individuals parasitologically examined, the prevalence of S. haematobium and S. mansoni were 4.2% and 2.4% respectively and the geometric mean egg count (GMEC) were 33.2 eggs/10 ml urine and 113.3 eggs/gram stools. Most of the patients with haematobiasis and mansoniasis were <15 years (56.4% & 53.8%), males (56.4% & 53.8%) & illiterates (46.2% & 46.2%). All cases were treated by Myrrh (Mirazid) as two capsules (600 mg) on an empty stomach an hour before breakfast for six consecutive days and were followed up clinically and parasitologically by urine analysis by the sedimentation and nucleopore techniques and by hatching test and by stool analysis by sedimentation and Kato-Katz techniques and by hatching test. The parasitological cure rate after three months was 97.4% and 96.2% for S. haematobium and S. mansoni cases with the marvelous clinical cure without any side-effects. Patients not completely responded to a single course of treatment showed marked reduction of egg intensity. It is concluded that Mirazid proved to be safe and very effective in treatment of S. haematobium and S. mansoni infections under field conditions.
Adult Animals